The Centre, which announced plans to encourage vaccinations against the human papilloma virus (HPV) through its immunisation programme, is exploring options to cap prices so that the vaccines to treat cervical cancer become more affordable, according to an ANI report, citing official sources.
Additionally, the government plans to boost HPV vaccination for cervical cancer prevention through Information, Education, and Communication (IEC) campaigns, the report added.
During her interim Budget presentation on 1 February, Union Finance Minister Nirmala Sitharaman emphasized the government’s intent to promote vaccination among girls aged 9-14 years to prevent cervical cancer nationwide.
Despite being highly preventable, cervical cancer ranks as the third most prevalent cancer in India, with an incidence rate of 18.3 per cent and the second highest mortality rate.
Nevertheless, HPV vaccination in young girls stands out as a pivotal measure in cervical cancer prevention efforts.
“HPV vaccination of young girls is the most remarkable and successful tool for cervical cancer prevention today. It is simple, safe, effective and feasible with existing infrastructure,” ANI quoted Dr Neerja Bhatla, Head of the Department of Obstetrics and Gynaecology at the All India Institute of Medical Sciences, Delhi, as saying.
For women over the age of 30, regular Pap smears and HPV tests can be helpful to prevent cervical cancer.
“Cervical cancer is a highly preventable cancer. Screening of women after the age of 30 with regular Pap smears and now with the HPV test is one strategy that has been successfully employed for several decades in developed countries but for universal coverage, it needs a lot of infrastructure and resources,” Dr Neerja added.
Dr Neerja said that cervical cancer vaccination can be a game changer. Recently, AIIMS Delhi conducted a study that showed that even a single dose of vaccine until the age of 20 is beneficial.
“At AIIMS, we conducted and participated in trials that showed that the number of doses could be decreased from three to two doses, and more recently, our data has supported only one dose until the age of 20 years. Implementing universal HPV vaccination in the national programme will be a game changer for a major public health problem,” she told ANI.
Following the Finance Minister’s Budget speech, Adar Poonawala, CEO of the Serum Institute of India, took to social media platform X to applaud the government’s announcement.
“I applaud the Indian government’s announcement to vaccinate girls aged 9-14 against cervical cancer. Let’s pledge to prevent HPV and ensure easy access to vaccination. Extending health cover for ASHA and Anganwadi workers, setting up more medical colleges, and streamlining maternal and child healthcare schemes demonstrate a holistic commitment to health,” he tweeted.
n 2022, Union Minister Jitendra Singh unveiled India’s inaugural homegrown vaccine, “CERVAVAC,” designed to combat cervical cancer.
The National Technical Advisory Group for Immunisation (NTAGI) has endorsed the inclusion of the quadrivalent Human Papilloma Virus (qHPV) vaccine into the Universal Immunization Programme (UIP), proposing a one-time catch-up for 9-14 year-old adolescent girls, followed by routine administration at nine years of age.
The vaccine administration will primarily occur within school premises, targeting students from grades 5 to 10. To ensure coverage for girls unable to attend school on the designated day, vaccination services will be available at health facilities. Additionally, out-of-school girls will be reached through Community Outreach and Mobile teams during the campaign.
Dr Sheetal Agarwal, Gynaecologist at Cloud9 Hospital said that there are two types of cervical vaccines.
“Gardasil, which is a quadrivalent vaccine, is given in three doses at zero, two and six months intervals. The other is Cervarix, which is bivalent vaccine, is given at zero, one and six months interval. The cost of both these vaccines – three doses – is within Rs 10000 and they should generally be administered prior to start of sexual activity” she told ANI.
Presently, the Serum Institute’s indigenous vaccine against cervical cancer, CERVAVAC, is available in the private market.
According to SII, it presently has a production capacity of around two- three million doses for the Cervavac vaccine. That said, the company plans to considerably expand this capacity, with a target of reaching 60-70 million doses and is priced at Rs 2000 per dose.
With inputs from agencies
Link to article –
Centre to encourage HPV vaccination for cervical cancer through price capping: Report
